Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients

By afschroeder • October 11, 2025

Eckardt MA, Siena NM, Copeland AR, McCaw TR, Shehata MS, Lofftus SY, Graham DS, Dao HB, Singh AS, Chmielowski B, Federman N, Kadera BE, Kalbasi A, Bernthal NM, Eilber FR, Dry SM, Nelson SD, Eilber FC, Crompton JG. Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients. Surgery. 2025 Oct 9;188:109610. doi: 10.1016/j.surg.2025.109610. Epub ahead of print. PMID: 41072121.

Tags: Hematology/Oncology, Publications

Related Posts

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram[...]

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]